Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

GYNAECOLOGICAL CANCER

First-line PARP inhibition in ovarian cancer — standard of care for all?

In 2018, the SOLO1 trial set a new standard of care with maintenance olaparib substantially extending progression-free survival (PFS) in women with newly-diagnosed BRCA1/2-mutated advanced-stage ovarian cancer. Herein, we summarize trials of first-line poly(ADP-ribose) polymerase (PARP) inhibition beyond BRCA1/2 mutations, including combination strategies, and discuss the optimum use of PARP inhibition in advanced-stage ovarian cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. George, A., Kaye, S. & Banerjee, S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat. Rev. Clin. Oncol. 14, 284–296 (2017).

    Article  CAS  Google Scholar 

  2. Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).

    Article  CAS  Google Scholar 

  3. Lord, C. J. & Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 19, 1381–1388 (2013).

    Article  CAS  Google Scholar 

  4. González-Martín, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019).

    Article  Google Scholar 

  5. Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019).

    Article  CAS  Google Scholar 

  6. Coleman, R. et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med. 381, 2403–2415 (2019).

    Article  CAS  Google Scholar 

  7. Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).

    Article  CAS  Google Scholar 

  8. Matthews, C. A. et al. Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a in BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. J. Clin. Oncol. 37 (Suppl. 15), 5541 (2019).

    Article  Google Scholar 

  9. Oaknin, A. et al. Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial. Ann. Oncol. 30 (Suppl. 5), mdz250.003 (2019).

    Google Scholar 

Download references

Acknowledgements

The authors acknowledge the National Institute for Health Research, Royal Marsden and ICR Biomedical Research Centre for Cancer. The work of C.J.L. is funded by Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre (CTR-Q4-Y2) and by a Cancer Research UK Programme Grant (CRUK/A14276).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Susana N. Banerjee.

Ethics declarations

Competing interests

S.B. has received honoraria as an advisory board member and/or giving lectures for AstraZeneca, Clovis, Genmabs, Merck Serono, Pharmamar, Roche, Seattle Genetics and Tesaro/GSK. C.J.L. has received research funding from Artios, AstraZeneca and Merck KGaA; has received honoraria as a consultant or senior advisory board for Artios, AstraZeneca, Gerson Lehrman Group, Merck KGaA, Ono Pharma, Sun Pharma, Syncona, Tango, Third Rock and Vertex; owns stock in Ovibio and Tango; and is a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from the development as part of the ICR Rewards to Inventors scheme.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Banerjee, S.N., Lord, C.J. First-line PARP inhibition in ovarian cancer — standard of care for all?. Nat Rev Clin Oncol 17, 136–137 (2020). https://doi.org/10.1038/s41571-020-0335-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-020-0335-9

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing